A brief was filed March 28, 2014 on behalf men who reportedly suffered heart attacks, strokes or other serious cardiovascular injuries due to their use of testosterone therapies. It asserts that theoretically thousands of additional claims could ultimately be filed against the manufacturer of AndroGel, Axiron and other manufacturers. The consolidation of these cases in the Northern District of Illinois will prevent duplicative discovery and inconsistent court rulings, and preserve the resources of the court, parties and witnesses.
Pfizer, Inc., a named defendant in the testosterone therapy cases, filed a response in opposition last week with the U.S. Judicial Panel on Multidistrict Litigation (JPML). They suggested the litigation should be limited only to claims involving testosterone drugs that are sold in gel form, such as AndroGel, Testim, Axiron and Foresta and eliminate cases involving Pfizer’s Dep-Testosterone injection. They further instructed that the product has only been named in four (4) cases and there are significant differences between these lawsuits and the rest of the litigation.
Several other drug manufacturers have already filed responses supporting the inclusion of all pending testosterone lawsuits in one MDL.
The U.S. JPML is expected to hear oral arguments to determine if they should centralize the testosterone litigation or not to at an upcoming hearing in Chicago on May 29, 2014.
If you or a loved one have taken any of the above mentioned drugs and have any questions, contact our experienced Low-T attorneys at Gallon, Takacs, Boissoneault and Schaffer.